An interventional study of Liberal and Restrictive in Cirrhosis, sponsored by Institute of Liver and Biliary Sciences, India. Withdrawn at 1 site in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-05.
Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment
Consecutive cirrhotics who present to emergency department of ILBS with documented or suspected sepsis induced hypotension with Hb \<8 gm/dl will be randomly assigned to restrictive (Target Hb 7-8 gm/dl) to liberal (Target Hb 10-11 gm/dl) group in a 1:1 proportion At admission, all patients will undergo physical examination and baseline investigations to identify site of sepsis. Enrolled patients will be given PRBC-transfusion (Not more than two units of PRBC/day) when they reach their assigned trigger value (Hb 7-8 g/dl or 10-11 g/dl ) during the entire ICU stay. All other interventions will be at the discretion of clinicians.
Exclusion Criteria:
2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
Biological: Liberal
To maintain the target Hemoglobin of 7 to 8 gm/dL.
Other: Restrictive
2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
To maintain the target Hemoglobin of 7 to 8 gm/dL.
Mortality in both groups
Time frame: 28 dyas
Improvement in vasopressors in both groups
Improvement is defined as tapering the dose of vasopressors
Time frame: 28 days
Incidence of complications in both groups
Time frame: 28 days
Length of ICU (Intensive Care Unit) stay
Time frame: 28 days
Requirement of mechanical ventilation in both groups
Time frame: 28 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is withdrawn, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Liver and Biliary Sciences, India